Aspects of the disclosure related to methods of administering LRRK2 inhibitors with peripheral blocker compounds for use in reducing peripheral side effects.

Aspects of the disclosure relate to methods of administering everolimus with peripheral blocker compounds for use in reducing peripheral side effects.

Aspects of the disclosure related to peripheral blocker compounds for use in reducing peripheral side effects of anti-CNS disease drugs.

Aspects of the disclosure related to methods of administering LXR agonists with peripheral blocker compounds for use in reducing peripheral side effects.

Described herein are compounds and compositions useful for preventing and/or treating a disease or condition, e.g., a disease or condition associated with activity of p97 protein, e.g., cancer or a neurodegenerative disorder. In one aspect, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables R¹, R², R³, R⁴, R⁵, R⁶, R⁷, m and n are as defined herein.

The present disclosure provides methods of screening DNA-encoded chemical libraries utilizing mirror-images of target molecules. These methods allow highly efficient selection of compounds that bind to a target molecule, even when the target molecule can bind the DNA tag of the encoded compounds.

Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S are also provided

The present application discloses heteroaromatic and heterobicyclic aromatic derivative compounds and compositions, and methods for treating ferroptosis-related disorders and diseases in patients using the compounds and compositions as disclosed herein.

The present disclosure is directed to nitrogen-containing heteroaryl analogs, methods of making nitrogen-containing analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and/or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X₁, X₂, X₃, A₁, A₂, Y, R₁, R₂, R₃, and R₄ are as described herein.